Dr. J SkinClinic, Inc.
FDA inspection history in Cerritos, California, 2022 to 2026
- 2
- Form 483s
Every document, by year
- Form 483
2022: one Form 483; 2026: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2022One Form 483, at Cerritos, California.
- 2026One Form 483, at Cerritos, California.
- 2026The longest 483 on file: 7 observations over 7 pages at Cerritos, California.
Cited most
Across all Dr. J SkinClinic observations on file
- 21 CFR 211.180(c)General requirements3
- 21 CFR 211.166(a)Stability testing2
- 21 CFR 211.84(d)(1)Testing and approval or rejection of components, drug product containers, and closures2
- 21 CFR 211.100(b)Written procedures; deviations1
- 21 CFR 211.165(e)Testing and release for distribution1
The complete Dr. J SkinClinic file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Cerritos, California
Two Form 483s · 2022 to 2026 · 11 observations
Latest: Form 483, Mar 23, 2026 →
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2026-03-23 | 483 Form 483 | Cerritos, California | 7 | $99 |
| 2022-03-17 | 483 Form 483 | Cerritos, California | 4 | $99 |
Investigators on these documents
Devisree P. Mattigiri (1)Hung H. Do (1)Joshua S. Lee (1)Navneet Kaur (1)Wenzheng Zhang (1)
FEI number 3006185812 · most recent document Mar 23, 2026
About Dr. J SkinClinic, Inc.
How many FDA Form 483s has Dr. J SkinClinic, Inc. received?
FDA Intel has 2 Form 483s on file for Dr. J SkinClinic, Inc.; the most recent is dated Mar 23, 2026.
When was Dr. J SkinClinic, Inc. last inspected by FDA?
The most recent FDA inspection document on file for Dr. J SkinClinic, Inc. is a Form 483 dated Mar 23, 2026, for the site in Cerritos, California.
What did FDA cite at Dr. J SkinClinic, Inc.?
The regulations cited most in the observations on file for Dr. J SkinClinic, Inc. are 21 CFR 211.180(c) (General requirements), 3 times; 21 CFR 211.166(a) (Stability testing), 2 times; 21 CFR 211.84(d)(1) (Testing and approval or rejection of components, drug product containers, and closures), 2 times.